解读全球制药企业50强榜单:中国创新药企距离“Big Pharma”还有多远

每日经济新闻
26 Jun

近日,美国《制药经理人》杂志发布2025年全球制药企业50强榜单。该榜单根据医药公司去年处方药的销售业绩,列出全球前50强生物制药公司,强生创新制药以557亿美元销售额蝉联榜首,艾伯维、默沙东紧随其后。《每日经济新闻》记者对比发现,诺和诺德凭借GLP-1药物司美格鲁肽首次进入前十位,默沙东从第四位升至第三位,主要得益于全球“药王”帕博利珠单抗(K药)的稳定增长,诺华则从第三位下滑到第七位。此外,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10